Shrum Brad, Costello Penny, McDonald Warren, Howlett Christopher, Donnelly Marisa, McAlister Vivian C
1 General Surgery Experimental Laboratory, University Hospital, London, ON, Canada ; 2 Department of Pathology, London Health Sciences Centre, London, ON, Canada.
Hepatobiliary Surg Nutr. 2016 Jun;5(3):204-8. doi: 10.21037/hbsn.2016.01.01.
Understanding the prognosis of hepatocellular carcinoma (HCC) informs plans for care. Tumor morphology and molecular markers have been correlated with outcomes. Three-dimensional tissue culture (3DTC) allows for direct in vitro measurement of a tumor's ability to grow and metastasize. The impact of chemotherapeutic agents, alone or in combinations, may also be measured.
All patients with a presumed diagnosis of HCC were eligible for this study including those undergoing resection, chemoembolization and transplantation. Concomitant diseases and outcomes were recorded. One mm(3) HCC specimens were grown in multiwell plates containing gel media, without and with chemotherapeutic agents.
Tumors were sampled from 17 patients. Only 13 had HCC, all of whom had liver transplantation. Of the confirmed HCC patients, 6 (46%) are alive and disease free 82 months following transplantation, 1 (7%) is alive with recurrence of disease and 6 (46%) died, with a mean survival of 12 months post liver transplant. Ten of thirteen 3DTC samples grew, having an average migration distance of 108.3µm in the first 24 hours. Two of three patients who had prior chemoembolization had successful 3DTC. Migration distances (µm) were 188.8±104.3, 104.5±111.7 and 39.6±32.4 for tumors categorized as high, intermediate and low grade, respectively. Tumor migration was inhibited by irinotecan, paclitaxel and docetaxel (-68%±7%, -61%±19% and -60%±21%, respectively) whereas the effect was variable with 5 fluorouracil (5FU) and doxorubicin (-12%±51% and 9%±76%, respectively).
It is feasible to grow tissue from HCC in 3DTC to study the tumor's capacity to grow and migrate and its responsiveness to commonly used chemotherapeutic protocols.
了解肝细胞癌(HCC)的预后有助于制定治疗计划。肿瘤形态和分子标志物已与预后相关。三维组织培养(3DTC)可直接在体外测量肿瘤的生长和转移能力。单独或联合使用化疗药物的影响也可进行测量。
所有疑似诊断为HCC的患者均符合本研究条件,包括接受手术切除、化疗栓塞和移植的患者。记录伴随疾病和预后情况。将1立方毫米的HCC标本在含有凝胶培养基的多孔板中培养,分别添加和不添加化疗药物。
从17例患者中采集肿瘤样本。仅13例确诊为HCC,均接受了肝移植。在确诊的HCC患者中,6例(46%)在移植后82个月存活且无疾病,1例(7%)存活但疾病复发,6例(46%)死亡,肝移植后的平均生存期为12个月。13个3DTC样本中有10个生长,在最初24小时内平均迁移距离为108.3微米。3例曾接受化疗栓塞的患者中有2例3DTC培养成功。高、中、低级别肿瘤的迁移距离(微米)分别为188.8±104.3、104.5±111.7和39.6±32.4。伊立替康、紫杉醇和多西他赛可抑制肿瘤迁移(分别为-68%±7%、-61%±19%和-60%±21%);而5-氟尿嘧啶(5FU)和阿霉素的效果则各不相同(分别为-12%±51%和9%±76%)。
通过3DTC培养HCC组织以研究肿瘤的生长和迁移能力及其对常用化疗方案的反应是可行的。